5 Best Fast Growth Stocks to Buy Now

2. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Number of Hedge Fund Shareholders: 67

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) has a growing pipeline of treatments for rare diseases, autoimmune conditions, and inflammatory diseases, which is propelling the company’s sales to new heights. Despite production pitfalls last year, Horizon still grew sales by nearly 50% to $3.23 billion, while EPS rebounded to $2.37.

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)’s growth will slow this year, with sales projected to climb to about $3.60 billion, with EBITDA coming in at $1.33 billion. But many of the company’s key products are growing sales rapidly. Thyroid eye disease treatment Tepezza has grown revenue by 37% year-over-year through the first nine months of 2022, while sales of gout treatment Krystexxa have grown by 27%.

Smart money ownership of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) jumped by 23% during Q2 to hit an all-time high, having more than tripled over the past four years. Several healthcare-focused funds are extremely bullish on HZNP, most notably John Paulson’s Paulson & Co, which owns 6.2 million shares on June 30 and has 24.4% 13F exposure to the stock, more than double the exposure it has compared to any other stock.